The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic role of BRAF mutation in malignant cutaneous melanoma.
 
Amikar Sehdev
Consulting or Advisory Role - Gerson Lehrman Group
 
Ross Hayden
No Relationships to Disclose
 
Mathew Joseph Kuhar
No Relationships to Disclose
 
Liang Cheng
No Relationships to Disclose
 
Simon John Warren
No Relationships to Disclose
 
Lawrence Aaron Mark
Research Funding - Kyowa Hakko Kirin
 
William Arthur Wooden
No Relationships to Disclose
 
Douglas Jay Schwartzentruber
Stock and Other Ownership Interests - QUIO
 
Theodore F. Logan
Consulting or Advisory Role - Prometheus
Research Funding - Abbott Laboratories (Inst); Abraxis BioScience (Inst); Acceleron Pharma (Inst); Amgen (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BioVex (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Dynavax Technologies (Inst); Eisai (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche (Inst); Synta (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)